Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

Neurology

Volumn 57, Issue 6, 2001, Pages 1080-1084

  Cook, Stuart D ^a,b   Quinless, J R ^a   Jotkowitz, A ^a   Beaton, P ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON; INTERFERON BETA SERINE; NEOPTERIN; NEUTRALIZING ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ACTIVITY; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RADIOASSAY; RADIOIMMUNOASSAY;

EID: 0035949741     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.6.1080     Document Type: Article

References (24)

1. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies
2. Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy
3. Neutralizing antibodies during treatment of multiple sclerosis with interferon β-1b: Experience during the first three years
4. Incidence of antibodies to interferon-β in patients treated with recombinant human interferon-β1a from mammalian cells
5. Neutralising and binding anti-interferon-β-1b (IFN-Β-1b) antibodies during IFN-Β-1b treatment of multiple sclerosis
6. Clinical significance of anti-IFN-αa antibody titres during interferon therapy
7. Resistance to recombinant interferon α-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies
8. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukemia: Dose dependency of response and frequency of neutralizing anti-interferon antibodies
9. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-α) during therapy for chronic hepatitis C
10. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: Development of neutralising interferon antibodies and possible loss of antitumor activity
11. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS
12. Incidence and significance of neutralizing antibodies to interferon beta 1-a in multiple sclerosis
13. Immunogenicity of interferon-β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration
14. The expression of potency of neutralizing antibodies for interferons and other cytokines
15. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive
16. Neopterin: A review
17. Neopterin - Its clinical use in urinalysis
18. Elevated neopterin levels in Guillain-Barré syndrome. Further evidence of immune activation
19. Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers
20. A comparative study of the relative bioavailability of different interferon beta preparations
21. Comparative study of the pharmacokinetic and pharmacologic effects of Betaseron and Avonex
22. In-vitro TNF-alpha, IL-2 and IFN-gamma production as markers of relapses in multiple sclerosis
23. Daily urinary neopterin excretion as an immunologic marker of disease activity in multiple sclerosis
24. Injecting rationale into interferon-β therapy